Theranica Reports Clinical Study Results of Nerivio Migraine Bioband for the Treatment of Migraine in Pregnant Women
Shots:
- The retrospective controlled survey study results published in Headache evaluating Nerivio, a drug-free, wearable, battery-operated stimulation device, wirelessly controlled by a smartphone application in 115 women aged 18-45yrs.
- The results showed no statistical difference b/w women with migraine who used the device during pregnancy throughout 3mos. postpartum, and for those who did not use during this period, 66.7% achieved pain relief @2hrs.
- The device is a safe treatment for migraine during pregnancy, not increasing the risk for adverse pregnancy outcomes. Nerivio, a novel, remote electrical neuromodulation (REN) prescribed wearable that stimulates upper arm peripheral nerves to induce conditioned pain modulation, treatment lasts 45min. and is used once every other day
Ref: prnewswire | Image: Theranica
Related News:- Theranica's Nerivio Wearable Device Receives CE Mark for Acute Treatment of Migraine in Europe
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
